Live Breaking News & Updates on United kingdom at cambridge university hospitals

Stay updated with breaking news from United kingdom at cambridge university hospitals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

First patient dosed with Sosei's oral immunotherapy drug

The first patient has been dosed with an orally available small molecule cancer immunotherapy drug, Sosei Group Corporation and Cancer Research UK have announced.

United-kingdom , London , City-of , Cambridge , Cambridgeshire , Bristi-basu , Sosei-heptare , Nigel-blackburn , Matt-barnes , Debashis-sarker , Sosei-heptares , King-college-london

First patient dosed with Sosei's oral immunotherapy drug

The first patient has been dosed with an orally available small molecule cancer immunotherapy drug, Sosei Group Corporation and Cancer Research UK have announced.

Cambridge , Cambridgeshire , United-kingdom , London , City-of , Sosei-heptare , Bristi-basu , Nigel-blackburn , Sosei-heptares , Matt-barnes , Debashis-sarker , United-kingdom-at-cambridge-university-hospitals

Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies Tokyo, Japan, London and Cambridge, UK, 10 August 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world-leader in GPCR-focused structure-based drug design (SBDD) and development, and Cancer Research UK, the world’s largest independent funder of cancer research, today announce that the first patient has been dosed in a Phase I/IIa

United-kingdom , Seoul , Soult-ukpyolsi , South-korea , Japan , Cambridge , Cambridgeshire , London , City-of , Tokyo , Frazer-hall , Shinichiro-nishishita